{"title": "El gobierno de Estados Unidos obtiene 3,2 millones de dosis de la vacuna contra la COVID-19 de Novavax", "author": "Novavax; Inc", "url": "https://www.prnewswire.com/news-releases/el-gobierno-de-estados-unidos-obtiene-3-2-millones-de-dosis-de-la-vacuna-contra-la-covid-19-de-novavax-848185397.html", "hostname": "prnewswire.com", "description": "/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnolog\u00eda dedicada al desarrollo y comercializaci\u00f3n de vacunas de pr\u00f3xima generaci\u00f3n para...", "sitename": "PR Newswire", "date": "2022-07-11", "id": null, "license": null, "body": null, "comments": "Share this article", "commentsbody": null, "raw_text": null, "text": "[Novavax, Inc.](/news/novavax%2C-inc./)\n11 Jul, 2022, 08:10 ET\n[]\n- El acuerdo proporcionar\u00e1 la primera opci\u00f3n de vacuna basada en prote\u00ednas en Estados Unidos, en espera de la autorizaci\u00f3n de uso de emergencia de la FDA y la recomendaci\u00f3n de los CDC\nGAITHERSBURG, Md., 11 de julio de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq:\n[NVAX](#financial-modal)), una empresa de biotecnolog\u00eda dedicada al desarrollo y comercializaci\u00f3n de vacunas de pr\u00f3xima generaci\u00f3n para enfermedades infecciosas graves, anunci\u00f3 hoy un acuerdo con el Departamento de Salud y Servicios Humanos (HHS) de Estados Unidos, en colaboraci\u00f3n con el Departamento de Defensa, para asegurar 3,2 millones de dosis iniciales de la vacuna de la COVID-19 de Novavax (NVX-CoV2373) en caso de que reciba la Autorizaci\u00f3n de uso de emergencia (EUA) de la Administraci\u00f3n de F\u00e1rmacos y Alimentos de Estados Unidos (FDA) y una recomendaci\u00f3n de los Centros para el Control y la Prevenci\u00f3n de Enfermedades (CENTROS PARA EL CONTROL Y LA PREVENCI\u00d3N DE ENFERMEDADES). La vacuna a base de prote\u00ednas de Novavax estar\u00e1 disponible de forma gratuita para los estados, jurisdicciones, socios farmac\u00e9uticos federales y centros de salud cualificados a nivel federal.\n\"Nos complace acercarnos un paso m\u00e1s para ofrecer potencialmente nuestra vacuna a m\u00e9dicos, organizaciones de atenci\u00f3n m\u00e9dica y consumidores que esperaban una opci\u00f3n de vacuna basada en prote\u00ednas\", destac\u00f3 Stanley C. Erck, presidente y consejero delegado de Novavax. \"Estamos agradecidos por el apoyo y la asociaci\u00f3n continuos del gobierno de Estados Unidos para llevar la vacuna de la COVID-19 de Novavax a Estados Unidos, y esperamos la decisi\u00f3n de la FDA sobre una autorizaci\u00f3n de uso de emergencia\".\nLa vacuna Novavax de la COVID-19 se cre\u00f3 utilizando la tecnolog\u00eda de nanopart\u00edculas recombinantes de Novavax para generar un ant\u00edgeno derivado de la prote\u00edna pico (S) del coronavirus y est\u00e1 formulada con el adyuvante Matrix-M\u2122 a base de saponina patentado de Novavax para mejorar la respuesta inmunitaria. La vacuna Novavax de la COVID-19 contiene ant\u00edgeno de prote\u00edna purificada y no puede replicarse ni causar COVID-19.\nEl 7 de junio de 2022, el Comit\u00e9 Asesor de Vacunas y Productos Biol\u00f3gicos Relacionados de la FDA\n[vot\u00f3 para recomendar](https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=2412235604&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D1931016299%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-06-07-FDA-Advisory-Committee-Recommends-Emergency-Use-Authorization-of-Novavax-COVID-19-Vaccine-for-People-Aged-18-Years-and-Older%26a%3Dvoted%2Bto%2Brecommend&a=vot%C3%B3+para+recomendar) que la FDA otorgue una EUA para la vacuna Novavax COVID-19 para personas mayores de 18 a\u00f1os. La FDA actualmente est\u00e1 revisando la solicitud de EUA de Novavax. Si se otorga la EUA, una posible recomendaci\u00f3n de pol\u00edtica de los CDC ser\u00eda el paso final antes de que puedan comenzar las inmunizaciones con la vacuna Novavax COVID-19.\nAutorizaci\u00f3n en Estados Unidos\nNVX-CoV2373 a\u00fan no ha sido autorizado para su uso en Estados Unidos.\nAcerca de NVX-CoV2373\nNVX-CoV2373 es una vacuna basada en prote\u00ednas dise\u00f1ada a partir de la secuencia gen\u00e9tica de la primera cepa de SARS-CoV-2, el virus que causa la enfermedad de la COVID-19. La vacuna se cre\u00f3 utilizando la tecnolog\u00eda de nanopart\u00edculas recombinantes de Novavax para generar un ant\u00edgeno derivado de la prote\u00edna S del coronavirus y est\u00e1 formulada con el adyuvante Matrix-M\u2122 a base de saponina patentado de Novavax para mejorar la respuesta inmunitaria y estimular altos niveles de anticuerpos neutralizantes. NVX-CoV2373 contiene ant\u00edgeno de prote\u00edna purificada y no puede replicarse ni causar COVID-19.\nLa vacuna Novavax COVID-19 est\u00e1 envasada como una formulaci\u00f3n l\u00edquida lista para usar en un vial que contiene 10 dosis. El r\u00e9gimen de vacunaci\u00f3n requiere dos dosis de 0,5 ml (5 mcg de ant\u00edgeno y 50 mcg de adyuvante Matrix-M) administradas por v\u00eda intramuscular con 21 d\u00edas de diferencia. La vacuna se almacena entre 2\u00b0 y 8\u00b0 Celsius, lo que permite utilizar los canales de suministro de vacunas y de cadena de fr\u00edo existentes. El uso de la vacuna est\u00e1 sujeto a las recomendaciones oficiales.\nNovavax ha establecido asociaciones para la fabricaci\u00f3n, comercializaci\u00f3n y distribuci\u00f3n de NVX-CoV2373 en todo el mundo. Las autorizaciones existentes aprovechan la asociaci\u00f3n de fabricaci\u00f3n de Novavax con Serum Institute of India, el fabricante de vacunas m\u00e1s grande del mundo por volumen. Posteriormente se complementar\u00e1n con datos de sitios de fabricaci\u00f3n adicionales a lo largo de la cadena de suministro global de Novavax.\nAcerca de los ensayos de fase 3 de NVX-CoV2373\nNVX-CoV2373 se est\u00e1 evaluando en dos ensayos fundamentales de fase 3.\nPREVENT-19 (PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19) es un ensayo aleatorio 2:1, controlado con placebo, observador ciego para evaluar la eficacia, seguridad e inmunogenicidad de NVX-CoV2373 con el adyuvante Matrix-M en 29.960 participantes mayores de 18 a\u00f1os en m\u00e1s de 119 localizaciones de Estados Unidos y M\u00e9xico. El criterio principal de valoraci\u00f3n para PREVENT-19 fue la primera aparici\u00f3n de la COVID-19 sintom\u00e1tico (leve, moderado o grave) confirmado por PCR con inicio al menos 7 d\u00edas despu\u00e9s de la segunda dosis en participantes adultos serol\u00f3gicamente negativos (para SARS-CoV-2) en base. El criterio de \u00e9xito estad\u00edstico inclu\u00eda un l\u00edmite inferior de IC del 95% >30%. Un criterio de valoraci\u00f3n secundario fue la prevenci\u00f3n de la COVID-19 sintom\u00e1tica moderada o grave confirmada por PCR. Ambos criterios de valoraci\u00f3n se evaluaron al menos siete d\u00edas despu\u00e9s de la segunda vacunaci\u00f3n del estudio en voluntarios que no hab\u00edan sido infectados previamente con SARS-CoV-2. En el ensayo, NVX-CoV2373 alcanz\u00f3 una eficacia global del 90,4m%. En general, fue bien tolerado y provoc\u00f3 una s\u00f3lida respuesta de anticuerpos tras la segunda dosis en ambos estudios. Los resultados completos del ensayo se publicaron en el\n[New England Journal of Medicine](https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=1156696737&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D4021142847%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D467849857%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2116185%25253Fquery%25253Dfeatured_home%2526a%253DNew%252BEngland%252BJournal%252Bof%252BMedicine%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+England+Journal+of+Medicine) (NEJM).\nLa expansi\u00f3n pedi\u00e1trica de PREVENT-19 es un ensayo aleatorizado, controlado con placebo y ciego para el observador 2:1 para evaluar la seguridad, la efectividad y la eficacia de NVX-CoV2373 con el adyuvante Matrix-M en 2.247 participantes adolescentes de 12 a 17 a\u00f1os de edad en 73 lugares de Estados Unidos, en comparaci\u00f3n con el placebo. En el ensayo pedi\u00e1trico, NVX-CoV2373 logr\u00f3 su criterio principal de valoraci\u00f3n de eficacia (no inferioridad de la respuesta de anticuerpos neutralizantes en comparaci\u00f3n con los participantes adultos j\u00f3venes de 18 a 25 a\u00f1os de PREVENT-19) y demostr\u00f3 una eficacia general del 80% en un momento en que la variante preocupante Delta fue la cepa circulante predominante en Estados Unidos. Adem\u00e1s, las respuestas inmunitarias fueron de dos a tres veces m\u00e1s altas en adolescentes que en adultos frente a todas las variantes estudiadas.\nPREVENT-19 se lleva a cabo con el apoyo del gobierno de Estados Unidos, incluyendo el Departamento de Defensa, la Autoridad de Investigaci\u00f3n y Desarrollo Biom\u00e9dico Avanzado (BARDA), parte de la Oficina del Subsecretario de Preparaci\u00f3n y Respuesta del HHS, y el Instituto Nacional de Alergias y Enfermedades Infecciosas, parte de los Institutos Nacionales de Salud del HHS. BARDA est\u00e1 proporcionando hasta 1.750 millones de d\u00f3lares bajo un acuerdo del Departamento de Defensa (# MCDC2011-001). La Oficina Ejecutiva del Programa Conjunto del Departamento de Defensa para la Defensa Qu\u00edmica, Biol\u00f3gica, Radiol\u00f3gica y Nuclear tambi\u00e9n proporciona fondos de hasta 45,7 millones de d\u00f3lares en virtud de un acuerdo separado. Hasta la fecha, el gobierno de Estados Unidos acord\u00f3 un pedido de 3,2 millones de dosis de NVX-CoV2373 en virtud de estos acuerdos existentes en caso de que NVX-CoV2373 reciba la aprobaci\u00f3n de la FDA y una recomendaci\u00f3n de los CDC. Novavax y el gobierno de Estados Unidos determinar\u00e1n el momento, el precio y las cantidades para la entrega de cualquier dosis adicional de NVX-CoV2373 con la autorizaci\u00f3n de uso de la FDA. Novavax tiene la intenci\u00f3n de buscar adquisiciones adicionales en Estados Unidos de dosis de NVX-CoV2373 y otras posibles formulaciones.\nAdem\u00e1s, un ensayo realizado en el Reino Unido con 14.039 participantes de 18 a\u00f1os o m\u00e1s se dise\u00f1\u00f3 como un estudio aleatorizado, controlado con placebo y ciego para el observador y logr\u00f3 una eficacia general del 89,7%. El criterio principal de valoraci\u00f3n se bas\u00f3 en la primera aparici\u00f3n de la COVID-19 sintom\u00e1tico (leve, moderado o grave) confirmado por PCR con inicio al menos siete d\u00edas despu\u00e9s de la segunda vacunaci\u00f3n del estudio en participantes adultos serol\u00f3gicamente negativos (para SARS-CoV-2) al inicio del estudio. Los resultados completos del ensayo se publicaron en\n[NEJM](https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=1798428274&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D203909216%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D3617137863%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2107659%2526a%253DNEJM%26a%3DNEJM&a=NEJM).\nAcerca del adyuvante Matrix-M\u2122\nEl adyuvante Matrix-M a base de saponina patentado de Novavax ha demostrado un efecto potente y bien tolerado al estimular la entrada de c\u00e9lulas presentadoras de ant\u00edgenos en el lugar de la inyecci\u00f3n y mejorar la presentaci\u00f3n de ant\u00edgenos en los ganglios linf\u00e1ticos locales, aumentando la respuesta inmunitaria.\nAcerca de Novavax\nNovavax, Inc. (Nasdaq:\n[NVAX](#financial-modal)) es una empresa de biotecnolog\u00eda que promueve la mejora de la salud a nivel mundial a trav\u00e9s del descubrimiento, desarrollo y comercializaci\u00f3n de vacunas innovadoras para prevenir enfermedades infecciosas graves. La plataforma de tecnolog\u00eda recombinante patentada de la compa\u00f1\u00eda aprovecha el poder y la velocidad de la ingenier\u00eda gen\u00e9tica para producir eficientemente nanopart\u00edculas altamente inmunog\u00e9nicas dise\u00f1adas para abordar las necesidades urgentes de salud global. NVX-CoV2373, la vacuna de la COVID-19 de la compa\u00f1\u00eda, recibi\u00f3 autorizaci\u00f3n condicional de m\u00faltiples autoridades reguladoras a nivel mundial, incluidas la Comisi\u00f3n Europea y la Organizaci\u00f3n Mundial de la Salud. La vacuna est\u00e1 siendo revisada actualmente por m\u00faltiples agencias reguladoras en todo el mundo y pronto estar\u00e1 bajo revisi\u00f3n en Estados Unidos para su uso en adultos, adolescentes y como refuerzo. Adem\u00e1s de su vacuna de la COVID-19, Novavax tambi\u00e9n est\u00e1 evaluando actualmente una vacuna candidata combinada contra la gripe estacional y la COVID en un ensayo cl\u00ednico de fase 1/2, que combina NVX-CoV2373 y NanoFlu*, su vacuna candidata en investigaci\u00f3n tetravalente contra la gripe, y tambi\u00e9n est\u00e1 evaluando una vacuna basada en la cepa \u00d3micron (NVX-CoV2515), as\u00ed como una vacuna bivalente basada en la cepa original/basada en \u00d3micron. Estas vacunas candidatas incorporan el adyuvante Matrix-M basado en saponina patentado de Novavax para mejorar la respuesta inmune y estimular altos niveles de anticuerpos neutralizantes.\nPara m\u00e1s informaci\u00f3n, visite\n[www.novavax.com](https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=407804529&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D4020219187%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3460980-1%2526h%253D3623927874%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3457869-1%252526h%25253D982408174%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3440781-1%25252526h%2525253D3964594936%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3395501-1%2525252526h%252525253D2463599076%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3392093-1%252525252526h%25252525253D203886192%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3387216-1%25252525252526h%2525252525253D3917401194%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3260461-1%2525252525252526h%252525252525253D2897486098%2525252525252526u%252525252525253Dhttp%25252525252525253A%25252525252525252F%25252525252525252Fwww.novavax.com%25252525252525252F%2525252525252526a%252525252525253Dwww.novavax.com%25252525252526a%2525252525253Dwww.novavax.com%252525252526a%25252525253Dwww.novavax.com%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.novavax.com%2526a%253Dwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com) y p\u00f3ngase en contacto con nosotros en\n*NanoFlu identifica un candidato a vacuna contra la gripe con nanopart\u00edculas de prote\u00edna de hemaglutinina recombinante (HA) producida por Novavax. Este candidato en investigaci\u00f3n se evalu\u00f3 durante un ensayo controlado de fase 3 realizado durante la temporada de gripe 2019-2020.\nDeclaraciones prospectivas\nDeclaraciones en este documento relacionadas con el futuro de Novavax, sus planes operativos y perspectivas, sus asociaciones, el potencial de pedidos posteriores del gobierno de Estados Unidos para dosis adicionales de NVX-CoV2373 y otras posibles formulaciones, el momento de los resultados de los ensayos cl\u00ednicos, el desarrollo continuo de NVX-CoV2373, una candidata a vacuna en investigaci\u00f3n contra la gripe estacional-COVID, el alcance, el momento y el resultado de futuras presentaciones y acciones regulatorias, incluso con respecto a una decisi\u00f3n de EUA de la FDA y una recomendaci\u00f3n potencial de los CDC para NVX-CoV2373, los planes de Novavax para complementar las autorizaciones existentes con datos de los sitios de fabricaci\u00f3n adicionales en la cadena de suministro global de Novavax, autorizaciones mundiales adicionales de NVX-CoV2373 para uso en adultos y adolescentes y como refuerzo, el impacto potencial y el alcance de Novavax y NVX-CoV2373 para abordar el acceso a la vacuna, controlar el poblaciones pand\u00e9micas y protectoras, y la eficacia, seguridad y utilizaci\u00f3n prevista de NVX-CoV2373 y expectativas administraci\u00f3n de NVX-CoV2373 son declaraciones prospectivas. Novavax advierte que estas declaraciones prospectivas est\u00e1n sujetas a numerosos riesgos e incertidumbres que podr\u00edan causar que los resultados reales difieran materialmente de los expresados o impl\u00edcitos en dichas declaraciones. Estos riesgos e incertidumbres incluyen, entre otros, desaf\u00edos para satisfacer, solo o junto con socios, varios requisitos de seguridad, eficacia y caracterizaci\u00f3n de productos, incluidos los relacionados con la calificaci\u00f3n del proceso y la validaci\u00f3n del ensayo, necesarios para satisfacer a las autoridades reguladoras aplicables; dificultad para obtener materias primas y suministros escasos; limitaciones de recursos, incluido el capital humano y la capacidad de fabricaci\u00f3n, sobre la capacidad de Novavax para seguir las v\u00edas regulatorias planificadas; desaf\u00edos para cumplir con los requisitos contractuales en virtud de acuerdos con m\u00faltiples entidades comerciales, gubernamentales y de otro tipo; y aquellos otros factores de riesgo identificados en las secciones \"Factores de riesgo\" y \"Discusi\u00f3n y an\u00e1lisis de la administraci\u00f3n de la situaci\u00f3n financiera y los resultados de las operaciones\" del Informe anual de Novavax en el Formulario 10-K para el a\u00f1o finalizado el 31 de diciembre de 2021 y los Informes trimestrales posteriores en Formulario 10-Q, tal como se present\u00f3 ante la Comisi\u00f3n de Bolsa y Valores (SEC). Advertimos a los inversores que no conf\u00eden demasiado en las declaraciones prospectivas contenidas en este comunicado de prensa. Le animamos a leer nuestras presentaciones ante la SEC, disponibles en\n[www.sec.gov](https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=1247393363&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D3970712789%26u%3Dhttps%253A%252F%252Fwww.sec.gov%26a%3Dwww.sec.gov&a=www.sec.gov) y [www.novavax.com](https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=720299952&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D2533066842%26u%3Dhttps%253A%252F%252Fwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com), para una discusi\u00f3n de estos y otros riesgos e incertidumbres. Las declaraciones a futuro en este comunicado de prensa se refieren solo a la fecha de este documento, y no asumimos ninguna obligaci\u00f3n de actualizar o revisar ninguna de las declaraciones. Nuestro negocio est\u00e1 sujeto a riesgos e incertidumbres sustanciales, incluidos los mencionados anteriormente. Los inversores, los inversionistas potenciales y otros deben considerar cuidadosamente estos riesgos e incertidumbres.\nContactos:\nInversores\nAlex Delacroix | 240-268-2022\n[[email protected]](/cdn-cgi/l/email-protection#412833012f2e37203720396f222e2c)\nMedios\nAli Chartan o Giovanna Chandler | 202-709-5563\n[[email protected]](/cdn-cgi/l/email-protection#79141c1d10183917160f180f1801571a1614)\nLogo -\n[https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg](https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=1312749985&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D4079784435%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg)\nSOURCE Novavax, Inc.", "language": null, "image": "https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg?p=facebook", "pagetype": "articles", "links": ["/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "https://portal.prnewswire.com/Login.aspx", "https://www.prnewswire.com/account/online-membership-form/", "https://gdpr.cision.com/", "https://portal.prnewswire.com/Login.aspx", "/", "/news-releases/", "/products/overview/", "/contact-us/", "#", "/news-releases/", "/news-releases/news-releases-list/", "/news-releases/all-public-company-news/", "/news-releases/english-releases/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/multimedia/multimedia-list/", "/news-releases/photos/photos-list/", "/news-releases/videos/videos-list/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/latest-news-topics/", "#", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/automotive-transportation-latest-news/aerospace-defense-list/", "/news-releases/automotive-transportation-latest-news/air-freight-list/", "/news-releases/automotive-transportation-latest-news/airlines-aviation-list/", "/news-releases/automotive-transportation-latest-news/automotive-list/", "/news-releases/automotive-transportation-latest-news/maritime-shipbuilding-list/", "/news-releases/automotive-transportation-latest-news/railroads-and-intermodal-transportation-list/", "/news-releases/automotive-transportation-latest-news/supply-chain-logistics-list/", "/news-releases/automotive-transportation-latest-news/transportation-trucking-railroad-list/", "/news-releases/automotive-transportation-latest-news/travel-list/", "/news-releases/automotive-transportation-latest-news/trucking-and-road-transportation-list/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/business-technology-latest-news/blockchain-list/", "/news-releases/business-technology-latest-news/broadcast-tech-list/", "/news-releases/business-technology-latest-news/computer-electronics-list/", "/news-releases/business-technology-latest-news/computer-hardware-list/", "/news-releases/business-technology-latest-news/computer-software-list/", "/news-releases/business-technology-latest-news/data-analytics-list/", "/news-releases/business-technology-latest-news/electronic-commerce-list/", "/news-releases/business-technology-latest-news/electronic-components-list/", "/news-releases/business-technology-latest-news/electronic-design-automation-list/", "/news-releases/business-technology-latest-news/financial-technology-list/", "/news-releases/business-technology-latest-news/high-tech-security-list/", "/news-releases/business-technology-latest-news/internet-technology-list/", "/news-releases/business-technology-latest-news/nanotechnology-list/", "/news-releases/business-technology-latest-news/networks-list/", "/news-releases/business-technology-latest-news/peripherals-list/", "/news-releases/business-technology-latest-news/semiconductors-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/financial-services-latest-news/accounting-news-issues-list/", "/news-releases/financial-services-latest-news/acquisitions-mergers-and-takeovers-list/", "/news-releases/financial-services-latest-news/banking-financial-services-list/", "/news-releases/financial-services-latest-news/bankruptcy-list/", "/news-releases/financial-services-latest-news/bond-stock-ratings-list/", "/news-releases/financial-services-latest-news/conference-call-announcements-list/", "/news-releases/financial-services-latest-news/contracts-list/", "/news-releases/financial-services-latest-news/cryptocurrency-list/", "/news-releases/financial-services-latest-news/dividends-list/", "/news-releases/financial-services-latest-news/earnings-list/", "/news-releases/financial-services-latest-news/earnings-forecasts-projections-list/", "/news-releases/financial-services-latest-news/financing-agreements-list/", "/news-releases/financial-services-latest-news/insurance-list/", "/news-releases/financial-services-latest-news/investment-opinions-list/", "/news-releases/financial-services-latest-news/joint-ventures-list/", "/news-releases/financial-services-latest-news/mutual-funds-list/", "/news-releases/financial-services-latest-news/private-placement-list/", "/news-releases/financial-services-latest-news/real-estate-list/", "/news-releases/financial-services-latest-news/restructuring-recapitalization-list/", "/news-releases/financial-services-latest-news/sales-reports-list/", "/news-releases/financial-services-latest-news/shareholder-activism-list/", "/news-releases/financial-services-latest-news/shareholder-meetings-list/", "/news-releases/financial-services-latest-news/stock-offering-list/", "/news-releases/financial-services-latest-news/stock-split-list/", "/news-releases/financial-services-latest-news/venture-capital-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "/news-releases/general-business-latest-news/awards-list/", "/news-releases/general-business-latest-news/commercial-real-estate-list/", "/news-releases/general-business-latest-news/corporate-expansion-list/", "/news-releases/general-business-latest-news/earnings-list/", "/news-releases/general-business-latest-news/environmental-social-governance-list/", "/news-releases/general-business-latest-news/human-resource-workforce-management-list/", "/news-releases/general-business-latest-news/licensing-list/", "/news-releases/general-business-latest-news/new-products-services-list/", "/news-releases/general-business-latest-news/obituaries-list/", "/news-releases/general-business-latest-news/outsourcing-businesses-list/", "/news-releases/general-business-latest-news/overseas-real-estate-list/", "/news-releases/general-business-latest-news/personnel-announcements-list/", "/news-releases/general-business-latest-news/real-estate-transactions-list/", "/news-releases/general-business-latest-news/residential-real-estate-list/", "/news-releases/general-business-latest-news/small-business-services-list/", "/news-releases/general-business-latest-news/socially-responsible-investing-list/", "/news-releases/general-business-latest-news/surveys-polls-and-research-list/", "/news-releases/general-business-latest-news/trade-show-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "#", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/consumer-technology-latest-news/artificial-intelligence-list/", "/news-releases/consumer-technology-latest-news/blockchain-list/", "/news-releases/consumer-technology-latest-news/cloud-computing-internet-of-things-list/", "/news-releases/consumer-technology-latest-news/computer-electronics-list/", "/news-releases/consumer-technology-latest-news/computer-hardware-list/", "/news-releases/consumer-technology-latest-news/computer-software-list/", "/news-releases/consumer-technology-latest-news/consumer-electronics-list/", "/news-releases/consumer-technology-latest-news/cryptocurrency-list/", "/news-releases/consumer-technology-latest-news/data-analytics-list/", "/news-releases/consumer-technology-latest-news/electronic-commerce-list/", "/news-releases/consumer-technology-latest-news/electronic-gaming-list/", "/news-releases/consumer-technology-latest-news/financial-technology-list/", "/news-releases/consumer-technology-latest-news/mobile-entertainment-list/", "/news-releases/consumer-technology-latest-news/multimedia-internet-list/", "/news-releases/consumer-technology-latest-news/peripherals-list/", "/news-releases/consumer-technology-latest-news/social-media-list/", "/news-releases/consumer-technology-latest-news/science-tech-engineering-math-list/", "/news-releases/consumer-technology-latest-news/supply-chain-logistics-list/", "/news-releases/consumer-technology-latest-news/wireless-communications-list/", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/energy-latest-news/alternative-energies-list/", "/news-releases/energy-latest-news/chemical-list/", "/news-releases/energy-latest-news/electrical-utilities-list/", "/news-releases/energy-latest-news/gas-list/", "/news-releases/energy-latest-news/general-manufacturing-list/", "/news-releases/energy-latest-news/mining-list/", "/news-releases/energy-latest-news/mining-metals-list/", "/news-releases/energy-latest-news/oil-energy-list/", "/news-releases/energy-latest-news/oil-and-gas-discoveries-list/", "/news-releases/energy-latest-news/utilities-list/", "/news-releases/energy-latest-news/water-utilities-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/environment-latest-news/conservation-recycling-list/", "/news-releases/environment-latest-news/environmental-issues-list/", "/news-releases/environment-latest-news/environmental-policy-list/", "/news-releases/environment-latest-news/environmental-products-services-list/", "/news-releases/environment-latest-news/green-technology-list/", "/news-releases/environment-latest-news/natural-disasters/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/aerospace-defense-list/", "/news-releases/heavy-industry-manufacturing-latest-news/agriculture-list/", "/news-releases/heavy-industry-manufacturing-latest-news/chemical-list/", "/news-releases/heavy-industry-manufacturing-latest-news/construction-building-list/", "/news-releases/heavy-industry-manufacturing-latest-news/general-manufacturing-list/", "/news-releases/heavy-industry-manufacturing-latest-news/hvac-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machinery-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machine-tools-metalworking-and-metallury-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/paper-forest-products-containers-list/", "/news-releases/heavy-industry-manufacturing-latest-news/precious-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/textiles-list/", "/news-releases/heavy-industry-manufacturing-latest-news/tobacco-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "/news-releases/telecommunications-latest-news/carriers-and-services-list/", "/news-releases/telecommunications-latest-news/mobile-entertainment-list/", "/news-releases/telecommunications-latest-news/networks-list/", "/news-releases/telecommunications-latest-news/peripherals-list/", "/news-releases/telecommunications-latest-news/telecommunications-equipment-list/", "/news-releases/telecommunications-latest-news/telecommunications-industry-list/", "/news-releases/telecommunications-latest-news/voip-list/", "/news-releases/telecommunications-latest-news/wireless-communications-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "#", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/consumer-products-retail-latest-news/animals-pets-list/", "/news-releases/consumer-products-retail-latest-news/beers-wines-and-spirits-list/", "/news-releases/consumer-products-retail-latest-news/beverages-list/", "/news-releases/consumer-products-retail-latest-news/bridal-services-list/", "/news-releases/consumer-products-retail-latest-news/cannabis-list/", "/news-releases/consumer-products-retail-latest-news/cosmetics-and-personal-care-list/", "/news-releases/consumer-products-retail-latest-news/fashion-list/", "/news-releases/consumer-products-retail-latest-news/food-beverages-list/", "/news-releases/consumer-products-retail-latest-news/furniture-and-furnishings-list/", "/news-releases/consumer-products-retail-latest-news/home-improvements-list/", "/news-releases/consumer-products-retail-latest-news/household-consumer-cosmetics-list/", "/news-releases/consumer-products-retail-latest-news/household-products-list/", "/news-releases/consumer-products-retail-latest-news/jewelry-list/", "/news-releases/consumer-products-retail-latest-news/non-alcoholic-beverages-list/", "/news-releases/consumer-products-retail-latest-news/office-products-list/", "/news-releases/consumer-products-retail-latest-news/organic-food-list/", "/news-releases/consumer-products-retail-latest-news/product-recalls-list/", "/news-releases/consumer-products-retail-latest-news/restaurants-list/", "/news-releases/consumer-products-retail-latest-news/retail-list/", "/news-releases/consumer-products-retail-latest-news/supermarkets-list/", "/news-releases/consumer-products-retail-latest-news/toys-list/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/health-latest-news/biometrics-list/", "/news-releases/health-latest-news/biotechnology-list/", "/news-releases/health-latest-news/clinical-trials-medical-discoveries-list/", "/news-releases/health-latest-news/dentistry-list/", "/news-releases/health-latest-news/fda-approval-list/", "/news-releases/health-latest-news/fitness-wellness-list/", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/health-insurance-list/", "/news-releases/health-latest-news/infection-control-list/", "/news-releases/health-latest-news/international-medical-approval-list/", "/news-releases/health-latest-news/medical-equipment-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/mental-health-list/", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/supplementary-medicine-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/sports-latest-news/general-sports-list/", "/news-releases/sports-latest-news/outdoors-camping-hiking-list/", "/news-releases/sports-latest-news/sporting-events-list/", "/news-releases/sports-latest-news/sports-equipment-accessories-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "/news-releases/travel-latest-news/amusement-parks-and-tourist-attractions-list/", "/news-releases/travel-latest-news/gambling-casinos-list/", "/news-releases/travel-latest-news/hotels-and-resorts-list/", "/news-releases/travel-latest-news/leisure-tourism-list/", "/news-releases/travel-latest-news/outdoors-camping-hiking-list/", "/news-releases/travel-latest-news/passenger-aviation-list/", "/news-releases/travel-latest-news/travel-industry-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "#", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "/news-releases/policy-public-interest-latest-news/advocacy-group-opinion-list/", "/news-releases/policy-public-interest-latest-news/animal-welfare-list/", "/news-releases/policy-public-interest-latest-news/congressional-presidential-campaigns-list/", "/news-releases/policy-public-interest-latest-news/corporate-social-responsibility-list/", "/news-releases/policy-public-interest-latest-news/domestic-policy-list/", "/news-releases/policy-public-interest-latest-news/economic-news-trends-analysis-list/", "/news-releases/policy-public-interest-latest-news/education-list/", "/news-releases/policy-public-interest-latest-news/environmental-list/", "/news-releases/policy-public-interest-latest-news/european-government-list/", "/news-releases/policy-public-interest-latest-news/fda-approval-list/", "/news-releases/policy-public-interest-latest-news/federal-and-state-legislation-list/", "/news-releases/policy-public-interest-latest-news/federal-executive-branch-agency-news-list/", "/news-releases/policy-public-interest-latest-news/foreign-policy-international-affairs-list/", "/news-releases/policy-public-interest-latest-news/homeland-security-list/", "/news-releases/policy-public-interest-latest-news/labor-union-news-list/", "/news-releases/policy-public-interest-latest-news/legal-issues-list/", "/news-releases/policy-public-interest-latest-news/natural-disasters-list/", "/news-releases/policy-public-interest-latest-news/not-for-profit-list/", "/news-releases/policy-public-interest-latest-news/patent-law-list/", "/news-releases/policy-public-interest-latest-news/public-safety-list/", "/news-releases/policy-public-interest-latest-news/trade-policy-list/", "/news-releases/policy-public-interest-latest-news/us-state-policy-news-list/", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "#", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/news-releases/multicultural-latest-news/native-american-list/", "/news-releases/multicultural-latest-news/african-american-related-news-list/", "/news-releases/multicultural-latest-news/asian-related-news-list/", "/news-releases/multicultural-latest-news/children-related-news-list/", "/news-releases/multicultural-latest-news/diversity-equity-inclusion/", "/news-releases/multicultural-latest-news/hispanic-oriented-news-list/", "/news-releases/multicultural-latest-news/lesbian-gay-bisexual-list/", "/news-releases/multicultural-latest-news/mens-interest-list/", "/news-releases/multicultural-latest-news/people-with-disabilities-list/", "/news-releases/multicultural-latest-news/religion-list/", "/news-releases/multicultural-latest-news/senior-citizens-list/", "/news-releases/multicultural-latest-news/veterans-list/", "/news-releases/multicultural-latest-news/women-related-news-list/", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/ae/ar/news-releases/", "/comunicados-de-prensa/", "/comunicados-para-a-imprensa/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/de/pressemitteilungen/", "/es/comunicados-de-prensa/", "/fr/communiques-de-presse/", "/it/comunicati-stampa/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/fi/lehdistotiedotteet/", "/sv/pressmeddelanden/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/guaranteed-paid-placement/", "/products/all-products/", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "#nav-mobile", "/", "https://portal.prnewswire.com", "/contact-us/", "javascript:void(0)", "/contact-us/", "/contact-us/", "tel:+1-888-776-0942", "javascript:void(0)", "#", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/business-technology-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/financial-services-latest-news/", "/news-releases/general-business-latest-news/", "/news-releases/consumer-technology-latest-news/", "/news-releases/energy-latest-news/", "/news-releases/environment-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/telecommunications-latest-news/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/health-latest-news/", "/news-releases/sports-latest-news/", "/news-releases/travel-latest-news/", "/news-releases/multicultural-latest-news/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/products/all-products/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/contact-us/#general", "/request-a-demo/", "/contact-us/#editorial", "/contact-us/#partnerships", "/contact-us/#media", "/contact-us/#worldwide", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/news-releases/canada-and-ontario-invest-in-improved-community-and-recreation-infrastructure-in-elora-and-guelph-867360798.html", "/news-releases/u-s-government-secures-3-2-million-doses-of-novavax-covid-19-vaccine-892645861.html", "/fr/news-releases/le-gouvernement-des-etats-unis-obtient-3-2-millions-de-doses-du-vaccin-novavax-contre-la-covid-19-800449184.html", "#", "/news/novavax%2C-inc./", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", null, "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=2412235604&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D1931016299%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-06-07-FDA-Advisory-Committee-Recommends-Emergency-Use-Authorization-of-Novavax-COVID-19-Vaccine-for-People-Aged-18-Years-and-Older%26a%3Dvoted%2Bto%2Brecommend&a=vot%C3%B3+para+recomendar", "https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=1156696737&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D4021142847%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D467849857%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2116185%25253Fquery%25253Dfeatured_home%2526a%253DNew%252BEngland%252BJournal%252Bof%252BMedicine%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+England+Journal+of+Medicine", "https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=1798428274&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D203909216%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3440781-1%2526h%253D3617137863%2526u%253Dhttps%25253A%25252F%25252Fwww.nejm.org%25252Fdoi%25252Ffull%25252F10.1056%25252FNEJMoa2107659%2526a%253DNEJM%26a%3DNEJM&a=NEJM", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=407804529&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D4020219187%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3460980-1%2526h%253D3623927874%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3457869-1%252526h%25253D982408174%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3440781-1%25252526h%2525253D3964594936%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3395501-1%2525252526h%252525253D2463599076%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3392093-1%252525252526h%25252525253D203886192%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3387216-1%25252525252526h%2525252525253D3917401194%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3260461-1%2525252525252526h%252525252525253D2897486098%2525252525252526u%252525252525253Dhttp%25252525252525253A%25252525252525252F%25252525252525252Fwww.novavax.com%25252525252525252F%2525252525252526a%252525252525253Dwww.novavax.com%25252525252526a%2525252525253Dwww.novavax.com%252525252526a%25252525253Dwww.novavax.com%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.novavax.com%2526a%253Dwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com", "https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=684009306&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D4084139586%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3460980-1%2526h%253D91088807%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3457869-1%252526h%25253D1725473980%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3440781-1%25252526h%2525253D2733326919%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3395501-1%2525252526h%252525253D853375093%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3392093-1%252525252526h%25252525253D1325598136%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3387216-1%25252525252526h%2525252525253D2935962557%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3260461-1%2525252525252526h%252525252525253D1508558197%2525252525252526u%252525252525253Dhttps%25252525252525253A%25252525252525252F%25252525252525252Fc212.net%25252525252525252Fc%25252525252525252Flink%25252525252525252F%25252525252525253Ft%25252525252525253D0%252525252525252526l%25252525252525253Den%252525252525252526o%25252525252525253D3158017-1%252525252525252526h%25252525252525253D3702938248%252525252525252526u%25252525252525253Dhttps%2525252525252525253A%2525252525252525252F%2525252525252525252Fwww.linkedin.com%2525252525252525252Fcompany%2525252525252525252Fnovavax%2525252525252525252F%252525252525252526a%25252525252525253DLinkedIn%2525252525252526a%252525252525253DLinkedIn%25252525252526a%2525252525253DLinkedIn%252525252526a%25252525253DLinkedIn%2525252526a%252525253DLinkedIn%25252526a%2525253DLinkedIn%252526a%25253DLinkedIn%2526a%253DLinkedIn%26a%3DLi&a=LinkedIn", "https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=1247393363&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D3970712789%26u%3Dhttps%253A%252F%252Fwww.sec.gov%26a%3Dwww.sec.gov&a=www.sec.gov", "https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=720299952&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D2533066842%26u%3Dhttps%253A%252F%252Fwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com", "/cdn-cgi/l/email-protection#412833012f2e37203720396f222e2c", "/cdn-cgi/l/email-protection#79141c1d10183917160f180f1801571a1614", "https://c212.net/c/link/?t=0&l=es&o=3589994-1&h=1312749985&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3589994-1%26h%3D4079784435%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/biotechnology-list/", "/news-releases/health-latest-news/infection-control-list/", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "tel:Cision%20Distribution%20888-776-0942", "javascript://Chat", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "https://twitter.com/PRNewswire", "https://www.facebook.com/PR-Newswire-26247320522/", "https://www.linkedin.com/company/pr-newswire/", "/products/communications-cloud/", "/products/marketing/", "/products/public-relations/", "/products/ir-compliance/", "/products/agency/", "https://www.smallbusinesspr.com/request_information", "/products/all-products/", "https://prnewswire.mediaroom.com/index.php", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "/contact-us/prnewswire-partners/", "/contact-us/become-a-partner/", "https://www.cision.com/careers/", "https://www.cision.com/about/accessibility/", "https://www.prnasia.com/", "https://prnewswire.com.br/", "https://www.newswire.ca/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/fi/lehdistotiedotteet/", "/fr/communiques-de-presse/", "/de/pressemitteilungen/", "/in/news-releases/", "/il/news-releases/", "/it/comunicati-stampa/", "https://prnewswire.com.mx/", "/ae/news-releases/", "https://www.prnewswire.com/ae/ar/news-releases/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/es/comunicados-de-prensa/", "/sv/pressmeddelanden/", "https://www.prnewswire.co.uk/", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "/contact-us", "/products/overview", "https://prnewswire.mediaroom.com/index.php", "", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "tel:Cision%20Distribution%20Helpline", "/terms-of-use/", "/privacy-policy/", "/prn-information-security-policy/", "/sitemap/", "/rss/", "/cookie-settings/", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "javascript://Chat"]}